The weight-loss drugmaker's Wegovy and Ozempic are among the most closely watched new medications in recent history, but face ...

We recently published an article titled Jim Cramer’s Game Plan: 15 Stocks in Focus. In this article, we are going to take a ...

Novo Nordisk stock gained, lifted by strong sales growth and guidance from the maker of Wegovy and Ozempic. Shares in Novo, one of Europe's largest listed companies, advanced nearly 3% in Denmark. Dig ...

Novo Nordisk (NVO) reports Q4 earnings with expectations of 86 cents EPS and $11.40B revenues. Stock down 29.55% YOY, 4.81% ...

Novo's earnings results Wednesday differ from Eli Lilly's, whose stock slid on slower-than-expected sales of weight loss ...

In a report released today, Michael Nedelcovych from TD Cowen maintained a Buy rating on Novo Nordisk (NVO – Research Report). The company’s ...

Geographically, Novo Nordisk posted a 30% sales increase in North America, benefiting from the U.S. market’s strong demand ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...

European shares were flat in early trade on Wednesday, as gains led by healthcare stocks following drugmaker Novo Nordisk's ...

Some you might hold only temporarily, while others you own for decades. David Jagielski (Eli Lilly): A forever stock you can ...

A slowdown in Google's cloud-computing sales helped drag down Alphabet's overall revenue growth to its lowest rate since 2023. Shares tumbled about 7% ...